2026 Return to Growth Likely Arrives: Long-term accomplished founder and management have shepherded SBC from a solo clinic in 2000 to a global cosmetic treatment center franchiser and cash generation machine with little debt. Near-term revenue growth decline in 2025 on pricing pressures (reflecting increased market competition pressure) appears to now be completed. Accordingly, the Company should likely begin to grow anew going forward with additional prospects, global and Japanese M&A targets, and AI and Longevity initiatives. The recent small founder share sale is positive for trading liquidity (i.e., management remains confident in operating strategy). SBC
